482 related articles for article (PubMed ID: 19845567)
1. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
Modlin IM; Pavel M; Kidd M; Gustafsson BI
Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
[TBL] [Abstract][Full Text] [Related]
2. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
Hofsli E
Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
[TBL] [Abstract][Full Text] [Related]
3. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
Öberg K; Lamberts SW
Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
[TBL] [Abstract][Full Text] [Related]
5. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
6. The somatostatin receptor subtype 5 in neuroendocrine tumours.
van der Hoek J; Lamberts SW; Hofland LJ
Expert Opin Investig Drugs; 2010 Mar; 19(3):385-99. PubMed ID: 20151855
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin and somatostatin receptors: from basic concepts to clinical applications.
De Martino MC; Hofland LJ; Lamberts SW
Prog Brain Res; 2010; 182():255-80. PubMed ID: 20541669
[TBL] [Abstract][Full Text] [Related]
8. [Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours].
Uomo G; Germano D; Rabitti PG
Minerva Endocrinol; 2001 Dec; 26(4):225-9. PubMed ID: 11782707
[TBL] [Abstract][Full Text] [Related]
9. [New perspectives in diagnosis and therapy of endocrine gastroenteropancreatic (GEP) tumors with somatostatin analogues].
Rubello D; Rufini V; De Carlo E; Martini C; Calcagni ML; Sicolo N; Troncone L; Casara D
Minerva Endocrinol; 2003 Dec; 28(4):259-96. PubMed ID: 14752399
[TBL] [Abstract][Full Text] [Related]
10. [Gastroenteropancreatic neuroendocrine tumours (carcinoid tumours): definition, clinical aspects, diagnosis and therapy].
Bodelier AG; Haak HR
Ned Tijdschr Geneeskd; 2006 Aug; 150(34):1868-72. PubMed ID: 16970007
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.
Appetecchia M; Baldelli R
J Exp Clin Cancer Res; 2010 Mar; 29(1):19. PubMed ID: 20196864
[TBL] [Abstract][Full Text] [Related]
12. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
Massironi S; Conte D; Rossi RE
Scand J Gastroenterol; 2016; 51(5):513-23. PubMed ID: 26605828
[TBL] [Abstract][Full Text] [Related]
14. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.
Anthony LB; Woltering EA; Espenan GD; Cronin MD; Maloney TJ; McCarthy KE
Semin Nucl Med; 2002 Apr; 32(2):123-32. PubMed ID: 11965607
[TBL] [Abstract][Full Text] [Related]
15. Long-acting formulations of somatostatin analogues.
Anthony LB
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S216-8. PubMed ID: 10604134
[TBL] [Abstract][Full Text] [Related]
16. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
Ganetsky A; Bhatt V
Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
[TBL] [Abstract][Full Text] [Related]
17. [Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors].
Simonenko VB; Dulin PA; Makanin MA
Klin Med (Mosk); 2006; 84(4):4-8. PubMed ID: 16755846
[TBL] [Abstract][Full Text] [Related]
18. Future aspects of somatostatin-receptor-mediated therapy.
Oberg K
Neuroendocrinology; 2004; 80 Suppl 1():57-61. PubMed ID: 15477719
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic and diagnostic implications of the somatostatin system in gastroenteropancreatic neuroendocrine tumour disease.
Höcker M; Wiedenmann B
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S139-42. PubMed ID: 10604118
[TBL] [Abstract][Full Text] [Related]
20. Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours.
Srirajaskanthan R; Toumpanakis C; Meyer T; Caplin ME
Aliment Pharmacol Ther; 2009 Jun; 29(11):1143-54. PubMed ID: 19298583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
